Michelle E. Melisko

MD

Breast oncologist

About me

Dr. Michelle E. Melisko is a cancer specialist with expertise in caring for patients with breast cancer.

Also active in research, Melisko is interested in evaluating new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treating cancer that has spread to the brain. To foster more rapid advances in breast cancer treatment, she educates patients on clinical trials and encourages them to participate when appropriate.

Melisko earned her medical degree at the Wake Forest School of Medicine and completed a residency in internal medicine at Stanford Medicine. She completed a fellowship in hematology and oncology at UCSF.

  • Education

    Wake Forest University School of Medicine, 1997

  • Residencies

    Stanford Hospital and Clinics, Internal Medicine, 2000

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2003

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Hospice and Palliative Medicine, American Board of Internal Medicine

  • Academic Title

    Professor

Clinics I work with

Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

My reviews

4.9

Overall Experience
212 Reviews
Explained things in a way that was easy to understand
207 Reviews
Did the doctor pay attention to your concerns
207 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
208 Reviews
Knew the important information about your medical history
209 Reviews
The provider showed respect for what you had to say
209 Reviews
The provider spent enough time with me
210 Reviews
Decorative Caduceus

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

To evaluate the objective response rate in the Central Nervous System by composite response criteria in Cohort 1

Recruiting

Decorative Caduceus

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Length of subject survival after starting study treatment. A Gehan-like trial design with an interim futility analysis will be used.

Recruiting

Decorative Caduceus

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon...

Percentage of participants who are confirmed by independent central review to have achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (HR+, HER2 negativ...

Recruiting

Decorative Caduceus

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria

Recruiting

Decorative Caduceus

Olaparib In Metastatic Breast Cancer

RECIST 1.1 criteria will be reported with a two-sided 90% confidence interval using the method from Atkinson and Brown to account for the two-stage design

Recruiting

Share